Novo Nordisk and San Francisco-based Sempre Health have announced their collaboration on a pilot program that will offer diabetes medications through the latter company’s monetary incentive and SMS-driven prescription refill platform. The partnership is hoping to engage 10,000 diabetes patients on Sempre’s platform within 2018.
from MobiHealthNews https://ift.tt/2qNYFjt
April 19, 2018
Rose
MobiHealthNews
No comments
Related Posts:
Analyzing behavioral economics and psychology are key to engaging patients to make meaningful changesSo many well-meaning patient engagement efforts are based on a fallacy. The logical assumption is that by connecting patients with technology – equipping them with access to their personal health data or the educational … Read More
Microsoft announces closure of HealthVault Insights project; HealthVault platform unaffectedMicrosoft announced recently that it will be shuttering HealthVault Insights, the company’s app-based research project that used machine learning to help users analyze and access their personal health records. from MobiHealt… Read More
Fearing regulatory backlash, Nokia proactively removes pulse wave velocity feature from Body Cardio scaleNokia has announced that it will disable the pulse wave velocity measurement feature on its Withings’ Body Cardio scale as of January 24. The company said it is now learning the technology may require a different level of reg… Read More
In human-centric healthcare design, less is moreAmy Schwartz knows that product design isn’t just about making things look pretty. A trained cognitive psychologist, Schwartz said product design is about making devices usable and human-centered. from MobiHealthNews http://… Read More
At Mount Sinai, monetary incentives drive medication adherenceMount Sinai Health System is trying a new way to get high-risk patients to take their medications: financial incentives. Supported by a grant from Health 2.0 and the New York City Economic Development Corporation, the New Yor… Read More
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment